Mozavaptan Explained

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

• Spreitzer H . November 20, 2006 . Neue Wirkstoffe - Conivaptan . Österreichische Apothekerzeitung . 24/2006 . German .
• Web site: Conivaptan hydrochloride . Prous Science . Molecule of the Month . November 2006 . https://web.archive.org/web/20120213003638/http://www.prous.com/molecules/default.asp?ID=153. 2012-02-13.